問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5239Cases

2018-01-25 - 2021-12-31

Phase II

A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  • Condition/Disease

    IDIOPATHIC PULMONARY FIBROSIS

  • Test Drug

    CC-90001-IPF-001

Participate Sites
5Sites

Terminated4Sites

2017-12-01 - 2018-06-03

Phase III

A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    IMLYGIC

Participate Sites
6Sites

Terminated6Sites

2018-01-01 - 2020-05-01

Phase III

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Pimodivir combined with standard care treatment in adolescents, adults, and elderly hospitalized patients with influenza A

  • Condition/Disease

    Influenza A Infection

  • Test Drug

    Pimodivir

Participate Sites
5Sites

Terminated4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2018-06-01 - 2022-09-30

Phase III

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    ONIVYDE

Participate Sites
5Sites

Recruiting5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-03-31 - 2023-12-30

Phase II

A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    Moderate to Severe Active Systemic Lupus Erythematosus

  • Test Drug

    GDC-0853

Participate Sites
8Sites

Terminated6Sites

2018-03-01 - 2020-12-29

Phase I/II

An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

  • Condition/Disease

    Advanced Stage Newly Diagnosed Hodgkin Lymphoma

  • Test Drug

    ADCETRIS

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2018-03-01 - 2022-08-31

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)

  • Condition/Disease

    Venous thromboembolism

  • Test Drug

    Edoxaban

Participate Sites
5Sites

Recruiting5Sites

2018-03-23 - 2020-04-14

Phase III

A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

  • Condition/Disease

    Secondary Hyperparathyroidism/Hemodialysis

  • Test Drug

    Parsabiv

Participate Sites
13Sites

Terminated13Sites

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

  • Condition/Disease

    Previously Treated Unresectable Hepatocellular Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-06-01 - 2020-05-31

Phase I

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-228 (a Catalytic TORC1/2 Inhibitor) as Single Agent in Adult East Asian Patients with Advanced Nonhematological Malignancies

  • Condition/Disease

    Advanced Nonhematological Malignancies

  • Test Drug

    TAK-228

Participate Sites
1Sites

Terminated1Sites

1 421 422 423 424 425 524
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB